Search our Database of Scientific Publications and Authors

I’m looking for a

    13382 results match your criteria Atherosclerosis[Journal]

    1 OF 268

    Impact of flow-mediated dilatation and coronary calcification in providing complementary information on the severity of coronary artery disease.
    Atherosclerosis 2017 Nov 3;267:146-152. Epub 2017 Nov 3.
    Department of Medical Science and Cardiorenal Medicine, Yokohama City University, School of Medicine, Kanagawa, Japan.
    Background And Aims: Endothelial dysfunction and coronary artery calcification (CAC) may represent two distinct and separate processes in the development of coronary atherosclerosis. However, the interaction between these factors in determining the development of coronary artery disease (CAD) is uncertain.

    Methods: Brachial artery flow-mediated dilatation (FMD) was measured by high-resolution ultrasound before coronary angiography, in 156 patients undergoing coronary CT angiography on suspicion of CAD (M/F 100/56, age 67 ± 11yrs). Read More

    Circadian blood pressure patterns and blood pressure control in patients with chronic kidney disease.
    Atherosclerosis 2017 Oct 26;267:139-145. Epub 2017 Oct 26.
    HSR Pisana IRCCS, Rome, Italy. Electronic address:
    Background And Aims: Hypertension is a major risk factor for chronic kidney disease (CKD), and CKD progression is associated with suboptimal blood pressure (BP) control. Here we evaluate the impact of CKD on the attainment of BP control and the circadian BP profile in older subjects.

    Methods: In this observational study, we studied 547 patients referred to the hypertension clinic, of whom 224 (40. Read More

    Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals.
    Atherosclerosis 2017 Nov 1. Epub 2017 Nov 1.
    National & Kapodistrian University of Athens, School of Health Sciences, Department of Pharmacy, Laboratory of Biopharmaceutics-Pharmacokinetics, Athens, Greece. Electronic address:
    Background And Aims: We aimed to evaluate a possible atheroprotective effect of saffron aqueous extract (SFE), and its potential anti-inflammatory mechanisms, in apoE knockout (ApoE(-/-)) mice.

    Methods: Fifty male, ApoE(-/-) mice, fed a high-fat diet (HFD) for 12 weeks, were randomized into 5 groups: (1) baseline group, euthanatized, without intervention, (2) three saffron groups, receiving HFD and 30,60,90 mg/kg/day of SFE, respectively, for four weeks, per os through gavage, after reconstitution in water for injection (WFI), (3) control group (COG), receiving daily HFD and the same volume of WFI (four weeks). After blood sampling and euthanasia, aortic roots were excised and analyzed for gene expression and/or percentage of aortic stenosis, relative content of macrophages, smooth muscle cells (SMCs), connective tissue, tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases-2,-3,-9 (MMP-2,-3,-9) and their inhibitor (TIMP-2) and IL-6. Read More

    NLRP3 inflammasome pathways in atherosclerosis.
    Atherosclerosis 2017 Oct 22;267:127-138. Epub 2017 Oct 22.
    Department of Medicine, University of Cambridge, The West Forvie Building, Robinson Way, Cambridge, CB2 0SZ, UK. Electronic address:
    Atherosclerosis is the major cause of death and disability. Atherosclerotic plaques are characterized by a chronic sterile inflammation in the large blood vessels, where lipid-derived and damage-associated molecular patterns play important roles in inciting immune responses. Following the initial demonstration that NLR family Pyrin domain containing 3 (NLRP3) was important for atherogenesis, a substantial number of studies have emerged addressing the basic mechanisms of inflammasome activation and their relevance to atherosclerosis. Read More

    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis 2017 Oct 26;267:116-126. Epub 2017 Oct 26.
    Dept. of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
    Background And Aims: Activation of brown adipose tissue (BAT) reduces both hyperlipidemia and atherosclerosis by increasing the uptake of triglyceride-derived fatty acids by BAT, accompanied by formation and clearance of lipoprotein remnants. We tested the hypothesis that the hepatic uptake of lipoprotein remnants generated by BAT activation would be accelerated by concomitant statin treatment, thereby further reducing hypercholesterolemia and atherosclerosis.

    Methods: APOE*3-Leiden. Read More

    Cardiac involvement in myotonic dystrophy: The role of troponins and N-terminal pro B-type natriuretic peptide.
    Atherosclerosis 2017 Oct 21;267:110-115. Epub 2017 Oct 21.
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address:
    Background And Aims: Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are dominant inherited muscular dystrophies with multiple systemic involvement, often producing cardiac injury. This study sought to determine the clinical significance of elevated high sensitivity cardiac troponin T and I (hs-cTnT and hs-cTnI), and N-terminal pro B-type natriuretic peptide (NT-pro-BNP) in this population.

    Methods: Sixty DM patients (35 men and 25 women; mean age: 45. Read More

    Statin treatment in dialysis patients after acute myocardial infarction improves overall mortality.
    Atherosclerosis 2017 Oct 23. Epub 2017 Oct 23.
    Izmir Medicalpark Hospital, Department of Cardiology, Izmir, Karsiyaka, Turkey. Electronic address:
    While statins are widely accepted as a keystone for secondary prevention of cardiovascular disease in the general population, statin treatment in chronic renal failure is still debated. Statins have shown no benefit on cardiovascular outcomes in 4D, AURORA, and SHARP trials conducted in patients on dialysis. However, no study has yet compared statin treatment after acute myocardial infarction in end-stage renal disease (ESRD) patients. Read More

    HDL functionality in type 1 diabetes.
    Atherosclerosis 2017 Oct 21;267:99-109. Epub 2017 Oct 21.
    Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; School of Medicine, University of Western Australia, Perth, Australia. Electronic address:
    Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by absence of insulin secretion due to destruction of the pancreatic beta-cells. Patients with T1D exhibit an increased risk for cardiovascular disease (CVD) compared with non-diabetic subjects. It has been established that low concentration of high-density lipoprotein cholesterol (HDL-C), an independent risk marker of CVD, coincides with a reduced protective capacity against oxidative stress. Read More

    Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke: Methodological issues.
    Atherosclerosis 2017 Oct 24. Epub 2017 Oct 24.
    Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran; Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

    Ex vivo culture of human atherosclerotic plaques: A model to study immune cells in atherogenesis.
    Atherosclerosis 2017 Oct 7;267:90-98. Epub 2017 Oct 7.
    Section on Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
    Background And Aims: The mechanisms that drive atherosclerotic plaque progression and destabilization in humans remain largely unknown. Laboratory models are needed to study these mechanisms under controlled conditions. The aim of this study was to establish a new ex vivo model of human atherosclerotic plaques that preserves the main cell types in plaques and the extracellular components in the context of native cytoarchitecture. Read More

    Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque.
    Atherosclerosis 2017 Oct 14;267:78-89. Epub 2017 Oct 14.
    CVPath Institute, Inc., Gaithersburg, MD, USA. Electronic address:
    Background And Aims: Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzymatic inflammatory biomarker primarily bound to low-density lipoprotein cholesterol, is associated with an approximate twofold increased risk of cardiovascular disease and stroke. Despite indications that circulating Lp-PLA2 is sensitive to statins, it remains largely unknown whether statin usage exerts local effects on Lp-PLA2 expression at the site of atheromatous plaque.

    Methods: Carotid plaques (n = 38) were prospectively collected from symptomatic (n = 18) and asymptomatic (n = 20) patients with (n = 20) or without (n = 18) documented statin history. Read More

    A molecular intravascular ultrasound contrast agent allows detection of activated platelets on the surface of symptomatic human plaques.
    Atherosclerosis 2017 Oct 24;267:68-77. Epub 2017 Oct 24.
    Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany. Electronic address:
    Background And Aims: Activated platelets are amongst the most attractive imaging targets in atherosclerosis due to their important role in early processes of atherogenesis and thrombus formation. We developed a molecular intravascular ultrasound (IVUS) approach to detect activated platelets ex vivo on the surface of human plaques, using an IVUS system applied in clinical routine.

    Methods: Human carotid endarterectomy specimens were obtained directly from the operating room and exposed to artificial arterial flow conditions for incubation with the contrast agent. Read More

    Thoracic extra-coronary calcification for the prediction of stroke: The Multi-Ethnic Study of Atherosclerosis.
    Atherosclerosis 2017 Oct 7;267:61-67. Epub 2017 Oct 7.
    Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Medical Institutions, Baltimore, MD, USA. Electronic address:
    Background And Aims: Atherosclerosis is a systemic disease. We examined whether the cumulative burden of thoracic extra-coronary calcification (ECC) improves prediction of stroke, transient ischemic attack (TIA), and stroke mortality beyond traditional risk factors and coronary artery calcium (CAC).

    Methods: We followed a total of 6805 participants (mean age 62. Read More

    Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.
    Atherosclerosis 2017 Oct 20;267:49-60. Epub 2017 Oct 20.
    Lipoprotein Metabolism Section, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
    Apolipoprotein C-II (apoC-II) is a small exchangeable apolipoprotein found on triglyceride-rich lipoproteins (TRL), such as chylomicrons (CM) and very low-density lipoproteins (VLDL), and on high-density lipoproteins (HDL), particularly during fasting. ApoC-II plays a critical role in TRL metabolism by acting as a cofactor of lipoprotein lipase (LPL), the main enzyme that hydrolyses plasma triglycerides (TG) on TRL. Here, we present an overview of the role of apoC-II in TG metabolism, emphasizing recent novel findings regarding its transcriptional regulation and biochemistry. Read More

    Network analysis reveals a causal role of mitochondrial gene activity in atherosclerotic lesion formation.
    Atherosclerosis 2017 Oct 21;267:39-48. Epub 2017 Oct 21.
    Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität München, Munich, Germany; DZHK (German Research Centre for Cardiovascular Research), Munich Heart Alliance, Munich, Germany. Electronic address:
    Background And Aims: Mitochondrial damage and augmented production of reactive oxygen species (ROS) may represent an intermediate step by which hypercholesterolemia exacerbates atherosclerotic lesion formation.

    Methods: To test this hypothesis, in mice with severe but genetically reversible hypercholesterolemia (i.e. Read More

    Enlarged perivascular spaces in the basal ganglia are independently associated with intracranial atherosclerosis in the elderly.
    Atherosclerosis 2017 Oct 20;267:34-38. Epub 2017 Oct 20.
    Vanderbilt University Medical Center, Nashville, TN, USA.
    Background And Aims: Enlarged basal ganglia perivascular spaces (BG-PVS) are a marker of cerebral small vessel disease (SVD). The association between enlarged BG-PVS and atherosclerosis has been explored, but knowledge is limited to extracranial vessels. We aimed to assess whether enlarged BG-PVS correlate with carotid siphon calcifications (CSC), used as a surrogate of intracranial atherosclerosis. Read More

    Activation-induced FOXP3 isoform profile in peripheral CD4+ T cells is associated with coronary artery disease.
    Atherosclerosis 2017 Oct 20;267:27-33. Epub 2017 Oct 20.
    Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. Electronic address:
    Background And Aims: The expression of FOXP3 isoforms affects regulatory T (Treg) cell function. Reduced Treg cell function has been associated with coronary artery disease (CAD). However, alternative splicing of FOXP3 in CAD has not been investigated. Read More

    Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia.
    Atheroscler Suppl 2017 Nov 1;30:99-107. Epub 2017 Jun 1.
    Apheresis Center Rostock (ACR), Nephrocare Rostock GmbH, Nobelstr. 53, 18059 Rostock, Germany. Electronic address:
    Background And Aims: The objective of this study was a standardized comparison of the safety and effectiveness of the Kaneka (Kaneka Corporation, Osaka, Japan) whole blood (Liposorber DL-100) and plasma (Liposorber LA-15) lipoprotein apheresis (LA) system to optimize the individual therapy of patients with cardiovascular disease and severe dyslipidemia.

    Methods: Six chronic LA patients with a pre-treatment LDL-C < 6 mmol/l in steady state received a total of three treatments with the LA-15 device, followed by three treatments with the DL-100 device or vice versa. To achieve a standardized comparison the treated blood volume for any patient was kept identical for both procedures. Read More

    Impact of double filtration plasmapheresis on adhesion molecules levels in patients with stable coronary heart disease after coronary stenting.
    Atheroscler Suppl 2017 Nov 31;30:92-98. Epub 2017 May 31.
    Department of Nephrology and Blood Purification, Military Medical Academy, 6, Lebedeva Street, 194044 Saint-Petersburg, Russia.
    Objective And Methods: Endothelial dysfunction and inflammatory reaction at the site of damage plays a key role in the formation of neointimal hyperplasia, and in the progression of atherosclerosis. The initiating role in these processes is assigned to adhesion molecules. We studied the dynamics of the level of adhesion molecules soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), soluble form of the molecule platelet adhesion and endothelial type-1 (sPECAM-1), sL-, sP-, sE-selectins during double filtration plasmapheresis (DFPP) with use of plasma fractionators (PF) Cascadeflo EC-50W and EC-40W (Asahi Kasei Medical Co. Read More

    The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Atheroscler Suppl 2017 Nov 1;30:9-18. Epub 2017 Jun 1.
    Center of Endocrinology, Diabetes and Preventive Medicine (ZEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:
    The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein (LDL) receptor (LDLR) and directs it to the lysosome for degradation. This results in decreased numbers of LDLR available on the cell surface to bind LDL particles and remove them from the circulation and a subsequent increase in circulating LDL-cholesterol (LDL-C) concentrations. Since the role PCSK9 plays in LDL-C metabolism has been discovered in 2003, there have been major efforts in finding efficient and safe methods to inhibit it. Read More

    Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
    Atheroscler Suppl 2017 Nov;30:86-91
    Department of Internal Medicine and Medical Specialties, University of Rome 'Sapienza', Umberto I Hospital, Rome, Italy.
    Background: Hypercholesterolaemia is a major risk factor for cardiovascular disease and requires effective therapy in affected patients. Statins, the mainstay of lipid-lowering therapy, can cause side effects, including myalgia, in some patients. Ezetimibe, is frequently used as an add-on therapy for statins, and is also used as a monotherapy in statin-intolerant patients, however elevations in liver transaminases can occur. Read More

    Cascade screening for familial hypercholesterolemia: Practical consequences.
    Atheroscler Suppl 2017 Nov 1;30:77-85. Epub 2017 Jun 1.
    Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address:
    Familial Hypercholesterolemia (FH) is an autosomal dominant disorder mainly caused by mutations in the LDLR gene, resulting in elevated serum cholesterol levels and elevated risk of premature cardiovascular disease (CVD). Timely treatment with lipid lowering medication can lower the risk of CVD to the same level of the normal population. Currently the incidence of FH is estimated at 1 in 240 persons in the Caucasian population. Read More

    CaRe high - Cascade screening and registry for high cholesterol in Germany.
    Atheroscler Suppl 2017 Nov 1;30:72-76. Epub 2017 Jun 1.
    D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V., Hamburg, Germany; Synlab Academy, Synlab Holding Germany GmbH, Mannheim, Germany; Clinical Institut for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria; Medical Clinic V (Nephrology, Hypertension, Rheumatology, Endocrinology, Diabetology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.
    Introduction: Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. Read More

    Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism.
    Atheroscler Suppl 2017 Nov 1;30:63-71. Epub 2017 Jun 1.
    Department of Internal Medicine III, University Hospital Gießen and Marburg GmbH, Gießen, Germany.
    Background: Numerous healthcare studies have shown that more than 90% of all patients with dyslipidaemia are not treated adequately.

    Objectives: The "Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF)" [German Society of Lipidology], a non-profit professional membership organization, has already made a series of efforts to improve the care of patients suffering from dyslipidaemia. A recent outcome is the nationwide implementation and certification of Lipidological Competence Centres and Networks (LCCNs). Read More

    Analysis of lipid metabolism and its impact on the risk of ischemic heart disease in patients with definite familial hypercholesterolemia.
    Atheroscler Suppl 2017 Nov 1;30:56-62. Epub 2017 Jun 1.
    Lipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
    Aim: to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).

    Materials And Methods: 81 patients (middle age was 39.1 ± 0. Read More

    Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Atheroscler Suppl 2017 Nov 31;30:50-55. Epub 2017 May 31.
    Scientific Institute for Nephrology (WiNe), Düsseldorf, Germany.
    Background: In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system required a reassessment of the approval of chronic lipoprotein apheresis therapy for regular reimbursement. Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology. In 2009 the working group completed the indication for lipoprotein apheresis with respect to current cardiovascular guidelines and current scientific knowledge for the registry. Read More

    Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Atheroscler Suppl 2017 Nov 1;30:44-49. Epub 2017 Jun 1.
    Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany.
    According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. Read More

    Lipoprotein(a)-apheresis in the light of new drug developments.
    Atheroscler Suppl 2017 Nov 31;30:38-43. Epub 2017 May 31.
    Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstrasse 1, 80336 Muenchen, Germany. Electronic address:
    Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD). Recently <50 mg/dl was recommended as the desirable level for clinical use and decision making. All established medical therapies to lower cholesterol levels have no impact on lowering Lp(a) except niacin which is all too often poorly tolerated and not obtainable everywhere. Read More

    Management of patients with statin intolerance.
    Atheroscler Suppl 2017 Nov 1;30:33-37. Epub 2017 Jun 1.
    Lipidology, Department of Internal Medicine III, University Hospital Dresden Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr 74, 01307 Dresden, Germany.
    In recent years statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe. When the symptoms are alleviated and creatine kinase is normalized, re-exposition can be considered. Read More

    ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
    Atheroscler Suppl 2017 Nov 1;30:319-325. Epub 2017 Jun 1.
    Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
    Background And Aims: Cardiovascular disease is the major cause of morbidity and mortality in the world. Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk. Association studies suggest that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases, plays a role in the pathogenesis of diabetic nephropathy. Read More

    In vivo imaging of murine vasodynamics analyzing different mouse strains by optical coherence tomography.
    Atheroscler Suppl 2017 Nov 31;30:311-318. Epub 2017 May 31.
    Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany. Electronic address:
    Background And Aims: We tried to circumvent the limitations of standard organ chamber experiments using in vivo optical coherence tomography (OCT) to analyze the vascular function of small arteries in different mouse strains.

    Methods: OCT images were acquired with a two-axis galvanometer scanner head. Time series (3 frames per second, 300 × 512 pixel per frame) of cross-sectional images were analyzed with image processing software measuring the time course of vessel lumen dynamics. Read More

    Impact of omega-3 fatty acids on expression of angiogenic cytokines and angiogenesis by adipose-derived stem cells.
    Atheroscler Suppl 2017 Nov;30:303-310
    Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Electronic address:
    Background And Aims: Human adipose-tissue derived stem cells (ADSC) are interesting novel targets in tissue engineering and regenerative medicine with pronounced angiogenic capacities. Furthermore, omega-3 fatty acids have been described to mediate cardioprotective effects, but their role in angiogenesis and vascular regeneration is not well-understood. Here, we analyzed the impact of different omega-3 fatty acids on angiogenesis by ADSCs. Read More

    Lectin-like oxidized low-density lipoprotein receptor-1 promotes endothelial dysfunction in LDL receptor knockout background.
    Atheroscler Suppl 2017 Nov;30:294-302
    Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany. Electronic address:
    Objective: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor for oxidized LDL in endothelial cells. LOX-1 is highly expressed in atherosclerotic plaques. The impact of LOX-1 on development of endothelial dysfunction in large vessels in absence or presence of atherosclerosis-prone conditions has not been studied to date. Read More

    Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
    Atheroscler Suppl 2017 Nov 31;30:286-293. Epub 2017 May 31.
    Department of Gynecology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
    Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. Read More

    Therapeutic Plasma Exchange in a rare case myasthenic crisis after Botox injection.
    Atheroscler Suppl 2017 Nov 31;30:283-285. Epub 2017 May 31.
    Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Hemmat Highway, Tehran, Iran. Electronic address:
    Background And Aims: Botulinum toxin (Botox) injections are used as a cosmetic treatment to decrease wrinkles in face and chin. Being a neurotoxic agent it minimizes muscle activity, while side effects are usually rare. This article subsequently presents one case of these rare effects. Read More

    How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Atheroscler Suppl 2017 Nov 31;30:28-32. Epub 2017 May 31.
    Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
    Lipoprotein apheresis (LA) has been the last-resort therapeutic option in patients suffering from limited pharmaceutical options to lower highly elevated low density lipoprotein cholesterol (LDL-C) levels. Facing the introduction of the proprotein convertase subtilisin/kexine type 9 (PCSK-9) inhibitors, it has been speculated that they might replace LA to a large extend. Given an efficacy of approx. Read More

    Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins.
    Atheroscler Suppl 2017 Nov 1;30:278-282. Epub 2017 Jun 1.
    Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
    Introduction: Immunoadsorption (IA) is increasingly used instead of plasma exchange due to lower risk of side effects and a higher selectivity. As a consequence of the reduction of immunoglobulins (Ig), the rate of infectious complications might increase in those patients. We therefore aimed to investigate the infection rate following IA without intravenous IG (IVIG) substitution in our apheresis center, where patients do not receive IVIG on a regular basis. Read More

    Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris.
    Atheroscler Suppl 2017 Nov 3;30:271-277. Epub 2017 Jun 3.
    Department of Dermatology, University Hospital and Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. Electronic address:
    Background: Pemphigus vulgaris is a chronic autoimmune disease characterized by blisters and erosions forming in the mucous membranes and the skin. Many patients are severely impaired by pain, weight loss and increased risk of infections. The disease is mediated by specific autoantibodies directed against desmogleins that contribute to connect keratinocytes in the epidermis. Read More

    Immunoadsorption for treatment of severe atopic dermatitis.
    Atheroscler Suppl 2017 Nov 2;30:264-270. Epub 2017 Jun 2.
    Department of Dermatology, University Medical Center Mainz, Germany. Electronic address:
    Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Read More

    Immunoadsorption for autoimmune encephalitis.
    Atheroscler Suppl 2017 Nov 2;30:257-263. Epub 2017 Jun 2.
    Department of Neurology and Neurological Intensive Care Medicine, Specialist Hospital Hubertusburg, Wermsdorf, Germany.
    Autoimmune encephalitis is a severe inflammatory disorder of the brain. The discovery that several non-infectious forms of encephalitis are associated with autoantibodies was a breakthrough in the care of this previously untreatable group of patients. The correlation of antibody type and titer with pattern and severity of symptoms was essential for the initiation of immunotherapies. Read More

    Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.
    Atheroscler Suppl 2017 Nov 1;30:253-256. Epub 2017 Jun 1.
    University Hospital Carl-Gustav-Carus, Department of Medicine III, Division of Nephrology, Germany. Electronic address:
    ABO incompatible (ABOi) organ transplantation requires pre-transplant reduction of the recipient's IgG and IgM isoagglutinin titer against the donor to prevent hyperacute rejection. Over the past four years we primarily used unspecific IgG immunoadsorption (IA) for this purpose and combined this selectively with membrane filtration (IAc) to reduce IgM isoagglutinines. In patients with an initial IgG titer against donor below 1:64, plasma exchange (PE) was initiated. Read More

    Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Atheroscler Suppl 2017 Nov 3;30:246-252. Epub 2017 Jun 3.
    Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Electronic address:
    Objectives: Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing to premature and progressive CV events. Lipoproteinapheresis (LA) is the only efficacious therapy for reducing Lp(a). Data comparing the clinical efficacy of LA with respect to reduction of CV events in subjects with elevated Lp(a) versus LDL-C versus both disorders is scarce. Read More

    Dysregulation of the CD4(+) T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study.
    Atheroscler Suppl 2017 Nov 3;30:238-245. Epub 2017 Jun 3.
    Department of Endocrinology and Diabetes, Division of Diabetes and Nutritional Sciences, King's College London, London SE5 9NU, UK; Faculty of Medicine Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany; Department of Medicine III, Technische Universität Dresden, Dresden, Germany.
    Background And Aim: Lipoprotein-apheresis (LA) is a therapeutic approach used against severe forms of dyslipidemia in patients who are non-responders or intolerant to pharmacological treatments. However, little is known about the potential pleiotropic effects of LA, particularly regarding the immune system and its regulation. Thus, in an attempt to analyse the potential effects of dyslipidemia and LA on the regulation of CD4(+) T cells activation and lineage differentiation, we compared the CD4(+) T cells cytokines secretion profiles of dyslipidemic patients before and after LA with the profiles observed in healthy donors. Read More

    H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells.
    Atheroscler Suppl 2017 Nov 2;30:232-237. Epub 2017 Jun 2.
    Division of Nephrology, Department of Internal Medicine III, University Hospital and Faculty of Medicine Carl Gustav Carus at the Technische Universität, Dresden, Germany; Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine III, University Hospital and Faculty of Medicine Carl Gustav Carus at the Technische Universität, Dresden, Germany. Electronic address:
    Background: Severe forms of mono- and polygenetic hypercholesterolemia as well as elevated Lipoprotein (a) (LP(a)) with progressing cardiovascular (CV) disease are indication for lipoprotein apheresis (LA) in Germany. Many studies investigated pleiotropic effects of LA that might contribute to beneficial effects in advanced atherosclerosis. The present study aimed at investigating the potential role of Proangiogenic Cells (PAC) in patients with new onset or chronic LA using the heparin induced extracorporeal LDL-precipitation (H. Read More

    Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
    Atheroscler Suppl 2017 Nov;30:225-231
    Apherese Centrum Rostock (ACR), Nobelstraße 53, Rostock, Germany. Electronic address:
    Background: Lipidapheresis was introduced for intractable hyperlipidemia as a more selective therapy than plasma exchange aiming to enhance efficacy and limit side-effects. Although this therapy is regarded safe, multicenter data from routine application are limited. We investigated direct adsorption of lipoproteins (DALI) and lipofiltration (MONET) regarding the short and the long-term safety aspects. Read More

    Efficacy of lipid reduction with DALI and MONET.
    Atheroscler Suppl 2017 Nov 1;30:217-224. Epub 2017 Jun 1.
    Clinical and Epidemiological Research, Fresenius Medical Care, Else-Kroener-Strasse 1, Bad Homburg, Germany.
    Background: Lipidapheresis techniques are increasingly used to treat drug-resistant hyperlipidemia but few efficacy studies under routine application are available. In this multicenter observational study we investigated direct adsorption of lipoproteins (DALI) and lipoprotein filtration (MONET) for the short and the long-term effects on lipid-lowering effects.

    Methods: Data of 122 apheresis patients from 11 centers (DALI: n = 78, MONET: n = 44) were prospectively collected for a period of 2 years. Read More

    1 OF 268